Listen on the go
  • Listen on the Go
    • Faculty & Disclosures
    Prof. Peter Rossing

    Steno Diabetes Center Copenhagen, Herlev, Denmark

    Prof. Peter Rossing is head of complications research and chief physician at the Steno Diabetes Center Copenhagen, and professor in endocrinology with a focus on diabetic angiopathy at the University of Copenhagen. He leads a team dedicated to the research of micro-and macrovascular complications of diabetes and, since obtaining a specialist degree in internal medicine and endocrinology in 2004, has investigated the pathophysiology of the diabetic kidney at different stages, identifying several key risk markers for the development of diabetic nephropathy. read more

    He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving prognosis. In addition to studies on conventional antihypertensive agents, he has also been involved in some of the first studies of angiotensin II receptor blockers, aldosterone antagonists and, most recently, studies of direct renin inhibition with aliskiren in diabetic kidney disease.

    Prof. Rossing has co-authored over 570 publications and has an h–index of 79. He has received several national and international awards, including The Minkowski Prize from the European Association for the Study of Diabetes (EASD) in 2005, the Ruth Østerby Award from the European Diabetic Nephropathy Study Group in 2013, the EASD Camillo Golgi Prize in 2016, and the European Hormone Medal from the European Society of Endocrinology in 2022.

    Prof. Peter Rossing discloses: Consultancy fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim (BI), Eli Lilly and Company, Gilead, Merck Sharp and Dohme (MSD), Novo Nordisk and Sanofi. Grants/research support from AstraZeneca, Bayer and Novo Nordisk.
    Dr Eden Miller

    Diabetes and Obesity Care, Bend, Oregon, USA

    Dr Eden Miller, an Osteopathic Board-certified family practitioner, received her medical degree from Kirksville College of Osteopathic Medicine in 1997. She completed her residency in family practice at Eastmoreland Hospital in Portland, Oregon and recently completed her certification in obesity management. She is the founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care in Bend, Oregon, where she currently practices. read more

    Dr Miller cultivated a special interest in diabetes after contracting type 1 diabetes while in medical school and, from that personal experience, her practice has extended to subspecialize in diabetes care.

    An impassioned speaker, Dr Miller has given more than 1,250 lectures in the field of diabetes to healthcare professionals and patients alike, on subjects such as diabetes management, continuous glucose monitoring technology, insulin pump therapy, obesity and metabolism intervention, clinical research, and healthcare policy. Her adage for care is that “I only succeed as a provider if I turn patients into experts on their own disease.”

    Dr Miller believes that a physiologic, patient-individualized approach to diabetes intervention is crucial to success and that there needs to be a “collaborative effort” where patients are “unhindered by fear of personal scrutiny” and that “barriers for effective treatment need to be removed.”

    Dr Eden Miller discloses: Advisory board/panel fees from Abbott, Bayer, Eli Lilly and Company, and Novo Nordisk. Grants/research support from Abbott. Speaker’s bureau fees from Abbott, Bayer, Boehringer Ingelheim (BI), Eli Lilly and Company, and Novo Nordisk.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    touchCARDIO touchCARDIO
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Preventive Cardiology

    US Partner

    An Introduction to Preventive Cardiology

    Preventive cardiology covers all aspects of the prevention and lowering the risk of cardiovascular heart diseases and their complications, including reducing the risk of heart attacks and strokes. Consisting of primary and secondary prevention, preventive cardiology aims to reduce incidence and mortality stemming from diseases such as ischaemic heart disease. Methods to evaluate patient risks of developing cardiovascular diseases or suffering cardiovascular events, including examination of lifestyle and hereditary factors, other pre-existing conditions, cardiac imaging, diagnostic tests and more, can be used to identify patients who are most at-risk and provide multidisciplinary risk intervention to mitigate those risks and achieve heart-healthy lifestyles for patients.

    Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Preventive Cardiology Content

    Cardiovascular Risk, Cardiovascular Disease, Heart Failure, Myocardial Infarction, Preventive Cardiology, Stroke
    Watch Time: 38 mins
    touchIN CONVERSATION
    Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
    CE/CME ACCREDITED Prof. Peter Rossing, Dr Eden Miller Translations available:

    Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D

    Learning objectives
    Learning Objectives
    • Identify the epidemiological and pathophysiological drivers behind the progression of CKD
    • Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
    • Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
    Cardiovascular Risk, Atherosclerosis, Cardiovascular Disease, Preventive Cardiology
    Watch Time: 30 mins
    touchIN CONVERSATION
    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
    Prof. Kausik Ray, Dr. med. Mahir Karakas Translations available:

    Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias

    Learning objectives
    Learning Objectives
    • Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
    • Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
    • Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
    Preventive Cardiology
    Developed by Touch
    Peter Toth shares his highlights from the ASPC 2022 Congress on CVD Prevention!
    Watch Time: 3 mins

    Dr Peter Toth (President of the American Society for Preventive Cardiology [ASPC]) shares his highlights from the 2022 Congress on CVD Prevention. Find out more about the importance of the A, B, Cs of preventive cardiology and personalized patient care. Questions What were your highlights of the ASPC 2022 Congress on CVD Prevention? (00:15-00:52) 2. […]

    Atherosclerosis, Cardiovascular Disease, Preventive Cardiology
    generic_9.png
    Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
    Justin T Morrison, Judith Hsia, Marc P Bonaca

    Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14

    Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]

    Atherosclerosis, Preventive Cardiology
    Use of Coronary Computed Tomography for Calcium Screening of Atherosclerosis
    Joshua Beverly, Matthew J Budoff

    Heart International. 2020;14(2):76-9 DOI: https://doi.org/10.17925/HI.2020.14.2.76

    Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable to atherosclerosis.2 Moreover, the degree of coronary calcification strongly correlates with the magnitude of atherosclerotic plaque burden, […]

    Cardiovascular Disease, Preventive Cardiology
    Kazem Rahimi, ESC 2020 – Blood Pressure Lowering for Prevention of Cardiovascular Events
    Watch Time: 4.34 mins

    We spoke to Dr Kazem Rahimi (Oxford University, Oxford, UK) about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and their recent study examining blood pressure lowering to prevent cardiovascular events.  Questions Could you tell us a little about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and its objectives? (0.13) Could you give us […]

    Atrial Fibrillation, Preventive Cardiology
    Cardiovigilance in Atrial Fibrillation – Primordial to Quinary Prevention Intervention
    Kamal Kishor, Devendra Bisht, Sanjay Kalra

    European Journal of Arrhythmia & Electrophysiology. 2019;5(2):77–81 DOI: https://doi.org/10.17925/EJAE.2019.5.2.77

    Long-term follow-up of patients with atrial fibrillation (AF) has confirmed a significant increase in cardiovascular events, long-term risk of stroke, heart failure and all-cause mortality (89% in those with AF compared to 27% in those without AF).1 Not only is AF associated with a five-fold increased risk of stroke, AF-related stroke is also likely to […]

    Preventive Cardiology
    48/Application of the MADIT ICD Benefit Score to a tertiary UK centre primary prevention population
    N Jathanna (Presenting Author) – Nottingham University Hospitals NHS Trust, Nottingham; R Oliver – Nottingham University Hospitals NHS Trust, Nottingham; S Jamil-Copley – Nottingham University Hospitals NHS Trust, Nottingham

    European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr48

    Introduction: Guidelines recommend the implantation of primary prevention defibrillators (pICD) in patients with a left ventricular ejection fraction (LVEF) of <35% due to the associated higher risk of ventricular arrhythmias (VA) in this cohort. However, reported incidence of VA in this cohort is only 5–10%/year with many deaths occurring prior to VA events and up […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72